KRAS and ovarian carcinoma: We next dosed several KRAS mutant cell line derived xenograft (CDX) and patient‐derived xenograft (PDX) models including NSCLC, CRC, Pancreatic cancer, ovarian cancer, and esophageal cancer with IN10018.